CAC Software vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 70/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

CAC Software

by 4DMedical (Imbio CAC Software)

ElucidVivo A.3

by Elucid

AI Verdict

Tool A is specialized for quantifying coronary artery calcification from non-contrast CT scans, providing an Agatston score and other calcification metrics for risk assessment. Tool B offers a more comprehensive analysis of arterial plaque composition and stability from CT angiography, including calcifications, lipid-rich necrotic core, and fractional flow reserve. Therefore, Tool A is suitable for dedicated calcification scoring, while Tool B provides a broader assessment of plaque characteristics for atherosclerosis patient stratification.

Choose CAC Software if…

Choose Imbio's CAC Software if your primary goal is to quickly and non-invasively assess a patient's risk for coronary artery disease by quantifying coronary artery calcification from existing non-contrast chest CT scans. This tool is ideal for initial screening and risk stratification, providing an Agatston score and other calcification metrics to guide preventative care. It streamlines the analysis of calcification without requiring additional imaging protocols.

View CAC Software →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you need a detailed, quantitative analysis of arterial plaque composition and stability to stratify patients with atherosclerosis and optimize treatment decisions. This system is better suited when CT angiography has been performed, allowing for in-depth visualization and measurement of plaque characteristics like Lipid-Rich Necrotic Core (LRNC) and calcifications, validated against histology, to inform advanced cardiovascular management.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	CAC Software	ElucidVivo A.3
Deployment	Cloud-based (SaaS), integrates with PACS	Cloud and on-premise secure deployment.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

CAC Software

Tool A explicitly highlights its integration into existing DICOM viewing workflows and automated processes, which is crucial for seamless adoption in a busy clinical setting. While Tool B offers detailed visualization, Tool A's emphasis on fitting into current radiologist practices suggests a higher degree of immediate usability.

Clinical Value

ElucidVivo A.3

Tool B offers a more advanced and comprehensive assessment of atherosclerosis by quantifying arterial plaque composition and stability, including Lipid-Rich Necrotic Core (LRNC) and deriving fractional flow reserve (FFRct). Its validation against ground-truth histology further strengthens its clinical utility and predictive power beyond simple calcification scoring.

Pricing & Value

Tie

Both tools require direct contact for pricing information, indicating a lack of public transparency regarding their cost structures. Without specific pricing details or publicly available case studies on ROI, it is impossible to determine which offers better value.

Enterprise Readiness

CAC Software

Tool A explicitly confirms HIPAA compliance and the availability of a Business Associate Agreement (BAA), alongside offering versatile deployment options including cloud, on-premise, and partner platforms. Tool B's compliance and deployment details are less explicit in the provided information, making Tool A appear more robust for enterprise adoption.

Innovation

ElucidVivo A.3

Tool B demonstrates greater innovation by moving beyond basic calcification scoring to provide detailed quantitative analysis of arterial plaque composition and stability, including Lipid-Rich Necrotic Core (LRNC) and derived FFRct. This advanced characterization, validated by histology, offers deeper insights into disease progression and risk.

Support & Docs

CAC Software

Imbio (Tool A) provides transparent and easily accessible support options, including online case submission, phone, and email support with specified hours, and readily available FAQs. In contrast, specific support channels or documentation for ElucidVivo A.3 were not explicitly detailed in the available information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	CAC Software	ElucidVivo A.3
Name	CAC Software	ElucidVivo A.3
Company	Imbio	Elucid Bioimaging
Description Focus	Automated image post-processing for coronary artery calcification from non-contrast chest CT	Quantitative analysis of arterial plaque composition and stability from CT angiography
Key Output Metrics	Agatston score, arterial age, calcified lesion mass and volume	Quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications; derives fractional flow reserve (FFRct)
Imaging Modality	Non-contrast chest CT	CT angiography
Specialties	Cardiology, Radiology	Cardiology, Radiology, Vascular Surgery

Videos

Demos, reviews, and walkthroughs featuring CAC Software and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What type of imaging data is required for each tool?

Imbio's Coronary Artery Calcification (CAC) software analyzes non-contrast chest CT scans to determine coronary artery calcification. ElucidVivo A.3, on the other hand, requires CT angiography for its quantitative analysis of arterial plaque composition and stability.

What specific quantitative metrics do these tools provide for cardiovascular assessment?

Imbio's CAC Software outputs the Agatston score, arterial age, and calcified lesion mass and volume. ElucidVivo A.3 objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, and also derives fractional flow reserve (FFRct).

How do the primary analytical focuses of Imbio's CAC Software and ElucidVivo A.3 differ?

Imbio's CAC Software is designed to specifically identify and quantify calcification within the coronary arteries. ElucidVivo A.3 provides a broader analysis, focusing on the composition and stability of arterial plaque, including LRNC and matrix, in addition to calcifications.

Does either tool offer insights into plaque characteristics beyond just calcification?

Yes, ElucidVivo A.3 provides detailed visualization and measurement of lesion-level plaque composition, including Lipid-Rich Necrotic Core (LRNC) and matrix, which goes beyond simple calcification quantification. Imbio's CAC Software focuses specifically on the amount and location of coronary artery calcification.

How do these tools support patient risk stratification and treatment decisions?

Imbio's CAC Software supports risk assessment for coronary artery disease by quantifying calcification. ElucidVivo A.3 assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics validated against histology.

Is there a difference in the validation of the analytical results provided by these tools?

ElucidVivo A.3 explicitly states that its plaque characteristics are validated against ground-truth histology. The provided information for Imbio's CAC Software does not explicitly detail its validation methodology, though it is FDA-cleared.